 | |
- close
- close
| |||||||||
Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
 |
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
 |
|
| Operating Income | |
6.54B | 6.91B | 7.95B | 6.78B | 8.96B | |
|
| Gross Profit | |
23.0B | 25.4B | 27.7B | 29.9B | 32.7B | |
|
| Total Revenues | |
28.2B | 32.2B | 36.0B | 38.1B | 42.6B | |
|
| Net Income | |
5.77B | 6.14B | 7.02B | 6.54B | 8.16B | |
|
| Gross Margin | |
74.8% | 69.3% | 69.4% | 70.1% | 75.1% |   | |
| Research and Development Expense | |
4.17B | 4.80B | 5.32B | 6.43B | 7.22B | | |
| R&D/Sales Ratio | |
14.8% | 14.9% | 14.4% | 16.2% | 17.4% | | |
| Number of Drugs in Phase I | |
0 | 29.0 | 24.0 | 1.00 | 1.00 | | |
| Number of Drugs in Phase II | |
0 | 20.0 | 36.0 | 22.0 | 22.0 | | |
| Number of Drugs in Phase III | |
0 | 20.0 | 29.0 | 42.0 | 13.0 | | |
| Number of Drug Approvals | |
0 | 5.00 | 7.00 | 5.00 | 2.00 | | |
| New Drug Applications | |
0 | 8.00 | 8.00 | 0 | 0 | | |
| Return on Equity | |
0% | 0% | 0% | 0% | 0% | | |
| ||||||
|
|
